NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Active Not RecruitingPhase 1, Phase 2

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions: Type 1 Diabetes

Interventions: VX-264

Countries: United States, Canada, Germany, Italy, Netherlands, Switzerland, United Kingdom

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Key Inclusion Criteria:

Clinical history of T1D with greater than or equal to (\>=) 5 years duration Participant is on a stable diabetic treatment Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study

Key Exclusion Criteria:

Prior islet cell transplant, organ transplant, or cell therapy

Locations (16)

Miami, Florida, United States
Chicago, Illinois, United States
Boston, Massachusetts, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Madison, Wisconsin, United States
Edmonton, Canada
Montreal, Canada
Toronto, Canada
Vancouver, Canada
Dresden, Germany
Milan, Italy
Leiden, Netherlands
Geneva, Switzerland
Headington, United Kingdom
Newcastle upon Tyne, United Kingdom